Table 1.
Characteristics of the total sample of self-harming adolescents with depression, and a comparison between the adolescents with full-syndrome Borderline Personality Disorder (BPD) and with sub-threshold BPD at baseline and at trial completion
| Total | Full-syndrome BPD | Sub-threshold BPD | P | ||||
|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | |||||
| Girls | 34 (87.2) | 10 (100) | 24 (82.8) | .30 | |||
| Receiving DBT-A treatment | 21 (53.8) | 5 (50.0) | 16 (55.2) | 1.0 | |||
| History of psychiatric treatment | 22 (57.9) | 7 (70.0) | 15 (53.6) | .47 | |||
| 5 BPD criteria or more | 14 (35.9) | 10 (100) | 4 (13.8) | <.001 | |||
| MDD | 15 (38.5) | 4 (40.0) | 11 (37.9) | 1.0 | |||
| Dysthymia | 6 (15.4) | 1 (10.0) | 5 (17.2) | 1.0 | |||
| Depression NOS | 18 (46.2) | 5 (50.0) | 13 (44.8) | 1.0 | |||
| Any anxiety disorder | 19 (48.7) | 3 (30.0) | 16 (55.2) | .27 | |||
| Mean (SD) | n1 + n2 | Mean (SD) | n1 | Mean (SD) | n2 | ||
| Age, years | 15.8 (1.7) | 39 | 16.9 (1.7) | 10 | 15.5 (1.5) | 29 | .02 |
| SMFQ | |||||||
| Baseline | 16.3 (5.3) | 39 | 19.4 (4.7)a | 10 | 15.2 (5.1)c | 29 | .03 |
| -DBT | 21 | 17.2 (3.0) | 5 | 14.0 (5.4) | 16 | ||
| -EUC | 18 | 21.6 (5.4) | 5 | 16.8 (4.5) | 13 | ||
| Trial completion | 12.3 (6.2) | 39 | 16.5 (5.7)a | 10 | 10.8 (5.8)c | 29 | .01 |
| -DBT | 21 | 15.2 (5.7) | 5 | 9.1 (4.6) | 16 | ||
| -EUC | 18 | 17.8 (6.1) | 5 | 12.9 (6.5) | 13 | ||
| MADRS | |||||||
| Baseline | 22.1 (6.2) | 39 | 22.2 (5.7)a | 10 | 22.0 (6.4)c | 29 | .94 |
| -DBT | 21 | 26.2 (2.6) | 5 | 21.6 (7.2) | 16 | ||
| -EUC | 18 | 18.2 (5.1) | 5 | 22.6 (5.4) | 13 | ||
| Trial completion | 15.1 (8.1) | 39 | 20.5 (6.3)a | 10 | 13.3 (7.8)c | 29 | .01 |
| -DBT | 21 | 19.6 (8.6) | 5 | 10.3 (7.2) | 16 | ||
| -EUC | 18 | 21.4 (3.8) | 5 | 16.8 (7.2) | 13 | ||
| C-GAS | |||||||
| Baseline | 53.3 (7.0) | 39 | 52.1 (6.9)b | 10 | 53.7 (7.1)c | 29 | .56 |
| -DBT | 21 | 52.6 (7.2) | 5 | 54.0 (8.4) | 16 | ||
| -EUC | 18 | 51.7 (7.4) | 5 | 53.2 (5.6) | 13 | ||
| Trial completion | 64.1 (11.5) | 39 | 56.8 (6.6)b | 10 | 66.6 (11.9)c | 29 | .003 |
| -DBT | 21 | 59.4 (6.6) | 5 | 69.6 (9.2) | 16 | ||
| -EUC | 18 | 54.2 (6.1) | 5 | 62.9 (14.0) | 13 | ||
| SIQ-jr | |||||||
| Baseline | 39.9 (21.5) | 39 | 53.5 (23.1)b | 10 | 35.2 (19.1)c | 29 | .02 |
| -DBT | 21 | 45.3 (17.1) | 5 | 30.3 (14.6) | 16 | ||
| -EUC | 18 | 61.8 (27.1) | 5 | 41.2 (22.7) | 13 | ||
| Trial completion | 27.4 (20.0) | 39 | 34.1 (21.3)b | 10 | 25.1 (19.4)c | 29 | .23 |
| -DBT | 21 | 26.5 (6.3) | 5 | 16.4 (11.6) | 16 | ||
| -EUC | 18 | 41.7 (28.9) | 5 | 35.8 (21.9) | 13 | ||
| Lifetime episodes of self-harm (n) d | 49.0, 98.5 | 39 | 89.0, 239.5 | 10 | 44.0, 76.3 | 29 | .20 |
| n. of Axis 1 Disordersd | 2.0, 2.0 | 39 | 2.0, 2.0 | 10 | 2.0, 2.0 | 29 | .89 |
| n. of BPD-criteriad | 4.0, 2.0 | 39 | 6.0, 2.0 | 10 | 3.0, 2.0. | 29 | <.001 |
a A paired samples test showed a non-significant reduction in SMFQ (p = .16) and MADRS (p = .55) from baseline to trial completion
b A paired samples test showed a significant reduction in SIQ-jr (p = .01) and CGAS (p = .04) from baseline to trial completion
c A paired samples test showed a significant reduction in SMFQ (p = .001), MADRS (p < .001), CGAS (p < .001) and SIQ-jr (p = .04) from baseline to trial completion
d median, interquartile range